D
DiaMedica Therapeutics Inc. (DMAC)
NCM – Real vaqt narxi. Valyuta: USD
6.32
-0.13 (-2.02%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
6.32
-0.13 (-2.02%)
Yopilishda: May 12, 2026, 4:00 PM EDT
DiaMedica Therapeutics Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, og'ir ishemik kasalliklardan aziyat chekayotgan insonlarning hayotini yaxshilashga qaratilgan. Uning asosiy nomzodi DM199, inson to'qima kallikrein-1 oqsilining farmatsevtik faol rekombinant shakli bo'lib, u o'tkir ishemik insultni davolash bo'yicha 2/3-bosqich sinovlarida, shuningdek, preeklampsiya, kardio-buyrak kasalliklari va homila o'sishining sekinlashishini davolash bo'yicha 2-bosqichda. Kompaniya DM300ni ishlab chiqmoqda, bu o'tkir pankreatit kabi yallig'lanish kasalliklarini davolash uchun preklinik bosqichdagi rekombinant inson ulinastatinidir. Kompaniya ilgari DiaMedica Inc. nomi bilan tanilgan va 2016-yil dekabr oyida DiaMedica Therapeutics Inc. nomini o'zgartirgan. DiaMedica Therapeutics Inc. 2000-yilda tashkil etilgan va shtab-kvartirasi Minneapolis, Minnesota shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ambarish Shah Ph.D. | Chief Technology Officer |
| Dr. Julie Krop M.D. | Chief Medical Officer |
| Mr. Dietrich John Pauls MBA | President, CEO & Director |
| Mr. Dominic R. Cundari | Chief Commercial Officer |
| Mr. Scott Kellen CPA | CFO & Corporate Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 8-K | dmtp20260506_8k.htm |
| 2026-04-01 | DEFA14A | dmtp20260331_defa14a.htm |
| 2026-03-31 | 8-K | dmtp20260330_8k.htm |
| 2026-03-30 | 10-K | dmtp20251231_10k.htm |
| 2026-01-05 | 8-K | dmtp20260105_8k.htm |
| 2025-12-18 | 8-K | dmtp20251217_8k.htm |
| 2025-11-13 | S-8 | dmtp20251113_s8.htm |
| 2025-11-12 | 10-Q | dmtp20250930_10q.htm |
| 2025-08-20 | CORRESP | filename1.htm |
| 2025-08-12 | 8-K | dmtp20250812_8k.htm |